- Home
- DMA vs RAPT Comparison
DMA vs RAPT Comparison
Compare DMA & RAPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMA
- RAPT
- Stock Information
- Founded
- DMA 2011
- RAPT 2015
- Country
- DMA United States
- RAPT United States
- Employees
- DMA N/A
- RAPT N/A
- Industry
- DMA Trusts Except Educational Religious and Charitable
- RAPT Biotechnology: Pharmaceutical Preparations
- Sector
- DMA Finance
- RAPT Health Care
- Exchange
- DMA Nasdaq
- RAPT Nasdaq
- Market Cap
- DMA 78.6M
- RAPT 65.6M
- IPO Year
- DMA N/A
- RAPT 2019
- Fundamental
- Price
- DMA $8.82
- RAPT $1.05
- Analyst Decision
- DMA
- RAPT Hold
- Analyst Count
- DMA 0
- RAPT 10
- Target Price
- DMA N/A
- RAPT $5.00
- AVG Volume (30 Days)
- DMA 34.6K
- RAPT 1.1M
- Earning Date
- DMA 01-01-0001
- RAPT 11-12-2024
- Dividend Yield
- DMA 2.04%
- RAPT N/A
- EPS Growth
- DMA N/A
- RAPT N/A
- EPS
- DMA N/A
- RAPT N/A
- Revenue
- DMA N/A
- RAPT N/A
- Revenue This Year
- DMA N/A
- RAPT N/A
- Revenue Next Year
- DMA N/A
- RAPT N/A
- P/E Ratio
- DMA N/A
- RAPT N/A
- Revenue Growth
- DMA N/A
- RAPT N/A
- 52 Week Low
- DMA $4.78
- RAPT $1.00
- 52 Week High
- DMA $8.00
- RAPT $27.35
- Technical
- Relative Strength Index (RSI)
- DMA 52.84
- RAPT 32.76
- Support Level
- DMA $8.62
- RAPT $1.31
- Resistance Level
- DMA $9.00
- RAPT $1.96
- Average True Range (ATR)
- DMA 0.14
- RAPT 0.34
- MACD
- DMA -0.01
- RAPT -0.14
- Stochastic Oscillator
- DMA 56.10
- RAPT 2.16
About DMA Destra Multi-Alternative Fund
Destra Multi-Alternative Fund is a non-diversified, closed-end management investment company that operates as an interval fund with a continuous offering of fund shares. The investment objective of the fund is to seek returns from capital appreciation and income with an emphasis on income generation.
About RAPT RAPT Therapeutics Inc.
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.